Clinical Trial Results:
The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses
Summary
|
|
EudraCT number |
2021-000182-33 |
Trial protocol |
NL |
Global end of trial date |
21 Jan 2022
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Jan 2023
|
First version publication date |
21 Jan 2023
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
76421
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Radboudumc
|
||
Sponsor organisation address |
Geert Grooteplein Zuid 10, Nijmegen, Netherlands,
|
||
Public contact |
Konstantin Föhse, Radboudumc, konstantin.fohse@radboudumc.nl
|
||
Scientific contact |
Konstantin Föhse, Radboudumc, konstantin.fohse@radboudumc.nl
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
05 Jan 2023
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
21 Jan 2022
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
21 Jan 2022
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective is to analyze the effects of BNT162b2 vaccination on both the specific adaptive immune responses and the responsiveness of human immune cells upon stimulation with heterologous pathogens.
|
||
Protection of trial subjects |
Data from trial subjects was pseudonymized.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
18 Jan 2021
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Netherlands: 16
|
||
Worldwide total number of subjects |
16
|
||
EEA total number of subjects |
16
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
16
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||
Recruitment
|
|||||||||||
Recruitment details |
- | ||||||||||
Pre-assignment
|
|||||||||||
Screening details |
Healthcare workers from the Radboud University Medical Center, Nijmegen were enrolled who received the BNT162b2 mRNA COVID-19 vaccine as per national vaccination campaign and provided informed consent. Key exclusion criteria included a medical history of COVID-19. | ||||||||||
Period 1
|
|||||||||||
Period 1 title |
T3
|
||||||||||
Is this the baseline period? |
Yes | ||||||||||
Allocation method |
Not applicable
|
||||||||||
Blinding used |
Not blinded | ||||||||||
Arms
|
|||||||||||
Arm title
|
All participants | ||||||||||
Arm description |
According to inclusion criterion: subjects who were vaccinated with BNT162b2 as per national vaccination campaign | ||||||||||
Arm type |
Experimental | ||||||||||
Investigational medicinal product name |
BNT162b2
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Concentrate for solution for injection
|
||||||||||
Routes of administration |
Injection
|
||||||||||
Dosage and administration details |
30 µg
|
||||||||||
|
|||||||||||
Period 2
|
|||||||||||
Period 2 title |
T4
|
||||||||||
Is this the baseline period? |
No | ||||||||||
Allocation method |
Not applicable
|
||||||||||
Blinding used |
Not blinded | ||||||||||
Arms
|
|||||||||||
Arm title
|
All participants | ||||||||||
Arm description |
According to inclusion criterion: subjects who were vaccinated with BNT162b2 as per national vaccination campaign | ||||||||||
Arm type |
Experimental | ||||||||||
Investigational medicinal product name |
BNT162b2
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Concentrate for solution for injection
|
||||||||||
Routes of administration |
Injection
|
||||||||||
Dosage and administration details |
30 µg
|
||||||||||
|
|||||||||||
Period 3
|
|||||||||||
Period 3 title |
T5
|
||||||||||
Is this the baseline period? |
No | ||||||||||
Allocation method |
Not applicable
|
||||||||||
Blinding used |
Not blinded | ||||||||||
Arms
|
|||||||||||
Arm title
|
All participants | ||||||||||
Arm description |
According to inclusion criterion: subjects who were vaccinated with BNT162b2 as per national vaccination campaign | ||||||||||
Arm type |
Experimental | ||||||||||
Investigational medicinal product name |
BNT162b2
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Concentrate for solution for injection
|
||||||||||
Routes of administration |
Injection
|
||||||||||
Dosage and administration details |
30 µg
|
||||||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
All participants
|
||
Reporting group description |
According to inclusion criterion: subjects who were vaccinated with BNT162b2 as per national vaccination campaign | ||
Reporting group title |
All participants
|
||
Reporting group description |
According to inclusion criterion: subjects who were vaccinated with BNT162b2 as per national vaccination campaign | ||
Reporting group title |
All participants
|
||
Reporting group description |
According to inclusion criterion: subjects who were vaccinated with BNT162b2 as per national vaccination campaign |
|
|||||||||||||
End point title |
Neutralizing capacity of the serum against the D614G strain | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
T2 (Two weeks after the second dose)
T3 (Six months after the first dose)
T4 (Four weeks after the booster vaccination, which was approximately one year after the first dose).
|
||||||||||||
|
|||||||||||||
Notes [1] - 3 drop-outs because they had COVID-19 during study period |
|||||||||||||
Statistical analysis title |
Comparing geometric mean titers | ||||||||||||
Comparison groups |
All participants v All participants v All participants
|
||||||||||||
Number of subjects included in analysis |
39
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Parameter type |
Median difference (final values) | ||||||||||||
Confidence interval |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
Full study period
|
||
Assessment type |
Non-systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
25.1
|
||
Frequency threshold for reporting non-serious adverse events: 0% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: No adverse events were reported by the subjects. Common side effects of vaccination or blood collection were not regarded as adverse events, as pre-defined in the protocol. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |